

## Supplementary materials

### Treatment with Telitacicept

The patients were treated with subcutaneous injection of 80mg telitacicept every week.

**Supplemental Table S1.** characteristics of lupus nephritis patients

Parameters	N (%)
Age (years)	32.74±12.46
Sex, n (% female)	30(88.2%)
Disease duration (year)	7.92(6.76)
Skin	10(29.4%)
Arthritis	9(26.5%)
Serositis	5(14.7%)
Central nervous system	0(0.0%)
Blood system	24(70.6%)
SLEDAI-2K	11.24(4.74)
PGA	1.56(0.41)
IgA	2.09(0.79)
IgG	10.04(3.94)
IgM	0.88(0.45)
C3	0.65±0.30
C4	0.14±0.08
ANA positive	31(91.2%)
Anti-dsDNA	275.9 (271.5)
Glucocorticoid use at baseline	20.82 (15.63)
HCQ	31(91.2%)
MMF	21(61.8%)
CYC	7(20.6%)
LEF	1(2.9%)
THAL	0(0.0%)
Biopsy	
III	1(2.9%)
IV	1(2.9%)
III+V	3(8.8%)
IV+V	7(20.6%)
The ratio of urinary protein to creatinine	1.20 (1.70)
24h protein qualification	1323.5 (1565.7)

**Supplemental Table S2.** Characteristics of patients with hematologic abnormalities

Parameters	N (%)
Age (years)	32.78±11.01
Sex, n (% female)	35(97.2%)
Disease duration (year)	5.88(6.24)
Skin	23(63.9%)
Arthritis	15(41.7%)
Serositis	7(19.4%)
Central nervous system	2(5.6%)
kidney	18(50.0%)
SLEDAI-2K	10.67(4.89)
PGA	1.52(0.46)
IgA	2.37(0.99)
IgG	13.80 (7.66)
IgM	1.15(0.77)
C3	0.63(0.32)
C4	0.12(0.08)
ANA positive	34(94.4%)
Anti-dsDNA	382.0 (295.0)
Glucocorticoid use at baseline	23.68 (14.68)
HCQ	33(91.7%)
MMF	22(61.1%)
LEF	4(11.1%)
CYC	4(11.1%)
THAL	0(0.0%)
WBC	7.21(4.80)
Hb	102.5(24.1)
PLT	183.3(117.4)
Leukopenia (n=9)	
proportion	9(25.0%)
WBC: mean±SD	3.18±0.66
Anemia (n=29)	
proportion	29(80.6%)
Hb: mean ± SD	93.52±15.59
Thrombocytopenia (n=15)	
proportion	15(41.7%)
PLT: mean±SD	100.8±40.54